Prolensa 0.07% Ophthalmic Solution — Competitive Intelligence Brief

Prolensa 0.07% Ophthalmic Solution (Prolensa 0.07% Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology Small molecule

Target snapshot

Prolensa 0.07% Ophthalmic Solution (Prolensa 0.07% Ophthalmic Solution) — Nicole Fram M.D.. Prolensa is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prolensa 0.07% Ophthalmic Solution TARGET	Prolensa 0.07% Ophthalmic Solution	Nicole Fram M.D.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Prednisone and Aspirin	Prednisone and Aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination	Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)
Indomethacin suppository	Indomethacin suppository	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Nerkardou (5 mg) & (10 mg)	Nerkardou (5 mg) & (10 mg)	Genuine Research Center, Egypt	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-2
Aspirin (acetylsalicylic acid)	Aspirin (acetylsalicylic acid)	Swedish Medical Center	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Acid	Ibuprofen Acid	Reckitt Benckiser Healthcare (UK) Limited	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Experimental: Aspirin monotherapy	Experimental: Aspirin monotherapy	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) / Antiplatelet agent	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class